Terns Pharmaceuticals (NASDAQ: TERN)
Terns Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Terns Pharmaceuticals Company Info
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
News & Analysis
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns has a modest market cap of less than $800 million, and its possible upside could be massive.
Should You Invest in This Under-the-Radar Weight Loss Stock?
Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More
This biotech's data suggests that it could have an advantage in its target market.
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Terns Pharmaceuticals just proved that it's competitive in the weight loss field.
Why Shares of Terns Pharmaceuticals Soared This Week
The company is showing progress toward a NASH therapy.
The Promises Behind Terns' Multi-Pronged Pipeline
This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.